Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Weight Loss 1Preleukemia 1Ovarian Neoplasms 1Osteochondroma 1Obesity 1Non-alcoholic Fatty Liver Disease 1Nevus, Epithelioid and Spindle Cell 1Myelodysplastic Syndromes 1Malnutrition 1Lung Neoplasms 1Hematologic Neoplasms 1Glioblastoma 1Giant Cell Tumors 1Gastrointestinal Neoplasms 1Fibrosis 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Carcinoma, Merkel Cell 1Carcinoma, Lobular 1Carcinoma in Situ 1Barrett Esophagus 1

Interventions

Cisplatin 116Radiotherapy 84Paclitaxel 77Fluorouracil 62Carboplatin 41Drug Therapy 38pembrolizumab 33Irinotecan 33tislelizumab 27Docetaxel 26Neoadjuvant Therapy 24toripalimab 23Oxaliplatin 23Radiation 20sintilimab 19camrelizumab 19Esophagectomy 18130-nm albumin-bound paclitaxel 18Capecitabine 17Surgical Procedures, Operative 16Nivolumab 16Leucovorin 15Cetuximab 14TP protocol 12S 1 (combination) 12Radiotherapy, Intensity-Modulated 12Albumin-Bound Paclitaxel 12nimotuzumab 11apatinib 10Immune Checkpoint Inhibitors 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Sampling Studies × Clear all
NCT04666090 2025-05-15

Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Active not recruiting
42 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡